In the past, we have written about Xeljanz-related blood clots and Xeljanz pulmonary embolism risks, i.e., blood clots in the lung, which can lead to death in some cases. Recently, however, we saw there are some new clinical trial findings of serious infections linked to Xeljanz. In March 2020 the UK’s Medicines and Healthcare products … [Read more...]
Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots
There is a new Xeljanz drug safety warning about an increased risk of blood clots resulting in pulmonary embolism (PE) and deep vein thrombosis (DVT). From this PDF document, “Xeljanz to be used with caution for all patients at high risk of blood clots”, issued in October 2019 by the European Medicines Agency (EMA), we get these details: A review … [Read more...]
Xeljanz FDA Drug Safety Communication About Increased Risks of Blood Clots And Death
This Xeljanz FDA Drug Safety Communication was issued July 26, 2019: “FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)”. From that document we get the following information: The U.S. Food and Drug Administration has approved new … [Read more...]
Xeljanz Safety Concerns and New Precautions
You may have read our previous articles about Xeljanz and its risk of leading to Pulmonary Embolism or even death. In June, we posted "Xeljanz Related Blood Clots Can Cause Pulmonary Embolism (PE) Or Deep Vein Thrombosis (DVT) With Patient Deaths Possible" that provides information on the serious side effects found out through a post-marketing … [Read more...]
Serious Side Effects For Xeljanz 10 mg Dose Leads To European Drug Safety Regulatory Action
In May 2019 there was more drug safety regulatory action, this time from Europe, regarding the serious side effects associated with Xeljanz related blood clots. We get some details from this news report, “EMA Puts Temporary Restrictions on Tofacitinib Due to PE Risk”: The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment … [Read more...]
Birth Control Pills Series: Are the Current FDA Label Warnings Enough?
In the previous article of my blog series on Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz, I discussed the devastating side effects that can result from using these DRSP-containing birth control pills. For my final article in this series, I will discuss the current drug label warnings for these drugs, and contemplate whether these warnings … [Read more...]
Birth Control Pills Series: The Devastating Side Effects
The first article of my blog series on Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz discussed how Yaz in particular was marketed to treat premenstrual dysphoric disorder (PMDD)--before PMDD was even classified as a medical condition--so that the drug manufacturer, Bayer, could increase their profits. In this article, I will provide … [Read more...]